Cobenfy(Xanomeline/Trospium) vs. Clozapine for Treatment-Resistant Schizophrenia

Background: Treatment-resistant schizophrenia (TRS) poses significant therapeutic challenges. Although clozapine remains the gold-standard pharmacologic treatment for TRS, its clinical utility is hampered by severe side effects and intensive monitoring requirements. KarXT (Cobenfy), a combination of xanomeline and trospium chloride, represents a novel antipsychotic approach by targeting muscarinic M1/M4 receptors instead of dopamine D2 pathways. Hypothesis: KarXT offers comparable efficacy to clozapine with a more favorable safety and tolerability profile, making it a viable alternative for patients with TRS. Methods: A systematic review was conducted to identify studies from 2015–2025 evaluating KarXT in schizophrenia. Sources included PubMed, ClinicalTrials.gov, FDA databases, ICER reports, and peer-reviewed journals. Inclusion criteria included randomized controlled trials (RCTs), long-term extension studies, or economic evaluations that reported on clinical efficacy (e.g., PANSS scores), safety, relapse prevention, or cost utility. Results: Eight studies met inclusion criteria. KarXT demonstrated consistent reductions in PANSS scores, improved both positive and negative symptom domains, and exhibited a low incidence of extrapyramidal symptoms, weight gain, or sedation. Long-term data showed durable responses over 52 weeks. Although no direct comparison with clozapine exists, KarXT’s safety and minimal monitoring requirements offer distinct advantages. Conclusions: KarXT offers a promising antipsychotic alternative for TRS, particularly in patients unable or unwilling to use clozapine. Its unique mechanism and improved tolerability may support its integration earlier in clinical practice, though further comparative trials will be critical to define its optimal placement in the treatment sequence.